Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

by · The Cerbat Gem

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors acquired 1,002 put options on the stock. This represents an increase of approximately 1,791% compared to the average daily volume of 53 put options.

Insider Transactions at Maravai LifeSciences

In other Maravai LifeSciences news, CEO Bernd Brust acquired 216,212 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was purchased at an average price of $3.25 per share, with a total value of $702,689.00. Following the acquisition, the chief executive officer directly owned 466,771 shares of the company’s stock, valued at approximately $1,517,005.75. This trade represents a 86.29% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gregory T. Lucier bought 48,528 shares of the stock in a transaction dated Monday, December 8th. The shares were acquired at an average cost of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the acquisition, the director directly owned 155,123 shares of the company’s stock, valued at approximately $569,301.41. This trade represents a 45.53% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 566,771 shares of company stock valued at $1,880,244 in the last three months. Insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in MRVI. Nuveen LLC acquired a new position in shares of Maravai LifeSciences in the 1st quarter valued at about $666,000. Philosophy Capital Management LLC acquired a new stake in Maravai LifeSciences during the first quarter worth approximately $5,731,000. Jacobs Levy Equity Management Inc. increased its holdings in Maravai LifeSciences by 437.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 493,582 shares of the company’s stock worth $1,091,000 after purchasing an additional 401,673 shares in the last quarter. Strs Ohio acquired a new position in Maravai LifeSciences in the first quarter valued at approximately $429,000. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of Maravai LifeSciences by 88.6% during the 1st quarter. Parkman Healthcare Partners LLC now owns 660,000 shares of the company’s stock worth $1,459,000 after buying an additional 310,000 shares in the last quarter. 50.25% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $5.36.

View Our Latest Report on Maravai LifeSciences

Maravai LifeSciences Stock Down 0.5%

NASDAQ MRVI opened at $3.71 on Friday. The business has a fifty day moving average price of $3.37 and a two-hundred day moving average price of $2.79. The stock has a market capitalization of $948.68 million, a PE ratio of -4.42 and a beta of 0.33. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $6.21. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The business had revenue of $41.63 million during the quarter, compared to the consensus estimate of $49.02 million. Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. Equities analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Maravai LifeSciences Company Profile

(Get Free Report)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Read More